BIOLOGIC BONE PROTEIN PROMOTERS
The use of bone graft substitute materials is already well established and widely adopted in clinical practice today. However, delivery of biologic growth factors and proteins is not without its complications and can lead to additional side effects due to unwanted bone growth.
TRGYX-003 is a potential product candidate centred on a fibronectin-based bone growth protein promotor technology which has been developed by the University of Glasgow. It can safely potentiate both underlying growth proteins as well as any added synthetic analogues. e.g. BMP-2, BMP-7, VEGF, PDGF-BB.
Taragenyx is looking to in-licence this technology to develop a stand-alone bone graft substitute material for synthetic, allograft, and autograft bone mineral substrates.
Safer: Smaller dose able to potentiate existing growth factor proteins by 300 times.
Adaptable: Can be applied to synthetic and natural bone graft substitute materials.
Faster Healing: Leads to promoted healing in poor or compromised underlying bone stock.